NPCE vs PIII
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
NPCE presents a classic high-growth, high-risk medical device profile, characterized by a weak Piotroski F-Score of 3/9 and a lack of current profitability. While the company demonstrates strong top-line growth (23.9% YoY) and impressive gross margins (77.23%), its valuation is stretched with a Price/Book ratio of 27.07. The narrowing net losses and consistent earnings beats suggest a positive trajectory toward profitability, but high debt-to-equity (3.72) and bearish insider sentiment temper the bullish analyst consensus.
P3 Health Partners exhibits severe financial distress, characterized by a Piotroski F-Score of 4/9 which barely maintains a 'stable' rating despite catastrophic balance sheet metrics. The company is operating with negative equity (Price/Book: -0.05) and a critical liquidity crisis, evidenced by a Current Ratio of 0.24. Massive operating losses and a staggering ROE of -6952.57% indicate a failing business model. With a 5-year price decline of 99.5% and consistent earnings misses, the company faces significant insolvency risk.
Compare Another Pair
Related Comparisons
NPCE vs PIII: Head-to-Head Comparison
This page compares NeuroPace, Inc. (NPCE) and P3 Health Partners Inc. (PIII) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.